Progenics Pharmaceuticals, Inc. Presents Novel Monoclonal Antibodies against Clostridium difficile at the American Society of Microbiology Conference
Published: May 27, 2010
TARRYTOWN, N.Y. & SAN DIEGO, Calif.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the presentation of preclinical data on novel monoclonal antibodies against toxins produced by the bacterium Clostridium difficile (C. difficile). The monoclonal antibodies effectively neutralized the cell-killing activities of the toxins in vitro and significantly improved survival in a stringent animal model of C. difficile infection. C. difficile is the leading cause of hospital-acquired diarrhea in the United States and represents a growing global public health challenge. The monoclonal antibodies were identified as part of the Company’s ongoing drug discovery efforts in infectious diseases. The data were presented today at the 110th General Meeting of the American Society for Microbiology in San Diego.